High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation

Bone Marrow Transplant. 2019 Mar;54(3):481-484. doi: 10.1038/s41409-018-0328-9. Epub 2018 Aug 31.

Authors

Erica S Tsang¹, Diego Villa², Federica Loscocco³, Giuseppe Visani³, Maryse Power⁴, Barbara Guiducci³, Cristina Clissa³, Kevin Song⁴, Cynthia Toze⁴, Yasser Abou Mourad⁴, Heather Sutherland⁴, David Sanford⁴, Stephen H Nantel⁴, Laurie H Sehn⁵, David W Scott⁵, Kerry J Savage⁵, Joseph M Connors⁵, Alina S Gerrie^{5

4}, Alessandro Isidori³

Affiliations

¹ Department of Medicine, University of British Columbia, Vancouver, Canada.
² Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, Vancouver, Canada. dvilla@bccancer.bc.ca.
³ Hematology and Stem Cell Transplant Center, AORMN, Pesaro, Italy.
⁴ Leukemia/Bone Marrow Transplant Program of British Columbia and Division of Hematology, Vancouver General Hospital and BC Cancer, Vancouver, Canada.
⁵ Centre for Lymphoid Cancer and Division of Medical Oncology, BC Cancer, Vancouver, Canada.

PMID: 30171222
DOI: 10.1038/s41409-018-0328-9

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carmustine / pharmacology
Carmustine / therapeutic use
Cytarabine / pharmacology
Cytarabine / therapeutic use
Etoposide / pharmacology
Etoposide / therapeutic use
Female
Hematopoietic Stem Cell Transplantation / methods*
Hodgkin Disease / therapy*
Humans
Male
Melphalan / pharmacology
Melphalan / therapeutic use
Middle Aged
Recurrence
Transplantation Conditioning / methods*
Transplantation, Autologous / methods*
Young Adult

Substances

Cytarabine
Etoposide
Melphalan
Carmustine

Supplementary concepts

BEAM regimen